MGI Aloxi Oral Dose, Post-Operative Indications To Enter Phase III In 2004
Executive Summary
MGI Pharma plans to commence Phase III trials for an oral formulation of the intravenous anti-emetic Aloxi (palonosetron), as well as studies supporting a post-operative indication
You may also be interested in...
MGI Aloxi Launch Set For September; Indications Include Delayed Nausea
MGI Pharma plans to differentiate the antiemetic Aloxi (palonosetron) from other 5HT3 antagonists by highlighting a unique indication for delayed nausea in chemotherapy patients
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials